{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:55:31Z","timestamp":1790880931272,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cancer-related anorexia\/cachexia syndrome (CACS) is characterized by anorexia and loss of body weight. Evidence is insufficient to strongly endorse any pharmacologic agent for the treatment of CACS. In this systematic review, we assessed the efficacy of oral anamorelin treatment for patients with CACS. On July 6, 2022, we systematically searched the following databases for randomized controlled trials (RCTs) of adults with CACS comparing oral anamorelin versus placebo: CENTRAL, PubMed, EMBASE, and ICHUSHI. The primary outcomes were total body weight (TBW), patient-reported quality of life (QOL), and adverse events (AEs). Secondary outcomes included lean body mass (LBM), overall survival (OS), non-dominant hand grip strength (HGS), and appetite. We included seven RCTs with a total of 1944 CACS patients. Anamorelin significantly increased TBW (mean difference (MD) 1.73, 95% confidence interval (CI) 1.34\u20132.13,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.00001), LBM (MD 1.06, 95% CI 0.30\u20131.81,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006), and QOL (standardized mean difference (SMD) 0.16, 95% CI 0.04\u20130.27,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006) compared with placebo without a significant difference in all AEs, severe AEs, OS, HGS or appetite. Anamorelin may be an effective treatment for CACS patients; however, further studies are needed to confirm the efficacy and safety of this drug.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-42446-x","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T12:03:52Z","timestamp":1694693032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["The efficacy and safety of anamorelin for patients with cancer-related anorexia\/cachexia syndrome: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"13","author":[{"given":"Jumpei","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Mikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"da Silva Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"42446_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0149-2918(05)80001-3","volume":"69","author":"WD Dewys","year":"1980","unstructured":"Dewys, W. D. et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69, 491\u2013497. https:\/\/doi.org\/10.1016\/s0149-2918(05)80001-3 (1980).","journal-title":"Am. J. Med."},{"key":"42446_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ctrv.2015.09.002","volume":"41","author":"A Esposito","year":"2015","unstructured":"Esposito, A. et al. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. Cancer Treat. Rev. 41, 793\u2013797. https:\/\/doi.org\/10.1016\/j.ctrv.2015.09.002 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"42446_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/s1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12, 489\u2013495. https:\/\/doi.org\/10.1016\/s1470-2045(10)70218-7 (2011).","journal-title":"Lancet Oncol."},{"key":"42446_CR4","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1001\/archinte.1988.00380070082020","volume":"148","author":"DB Reuben","year":"1988","unstructured":"Reuben, D. B., Mor, V. & Hiris, J. Clinical symptoms and length of survival in patients with terminal cancer. Arch. Intern. Med. 148, 1586\u20131591 (1988).","journal-title":"Arch. Intern. Med."},{"key":"42446_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/45230","volume":"402","author":"M Kojima","year":"1999","unstructured":"Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656\u2013660. https:\/\/doi.org\/10.1038\/45230 (1999).","journal-title":"Nature"},{"key":"42446_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35051587","volume":"409","author":"M Nakazato","year":"2001","unstructured":"Nakazato, M. et al. A role for ghrelin in the central regulation of feeding. Nature 409, 194\u2013198. https:\/\/doi.org\/10.1038\/35051587 (2001).","journal-title":"Nature"},{"key":"42446_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.bjc.6604148","volume":"98","author":"F Strasser","year":"2008","unstructured":"Strasser, F. et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia\/cachexia: A randomised, placebo-controlled, double-blind, double-crossover study. Br. J. Cancer 98, 300\u2013308. https:\/\/doi.org\/10.1038\/sj.bjc.6604148 (2008).","journal-title":"Br. J. Cancer"},{"key":"42446_CR8","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1002\/cncr.24917","volume":"116","author":"K Lundholm","year":"2010","unstructured":"Lundholm, K. et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: A randomized double-blind study. Cancer 116, 2044\u20132052. https:\/\/doi.org\/10.1002\/cncr.24917 (2010).","journal-title":"Cancer"},{"key":"42446_CR9","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1210\/jc.2003-031768","volume":"89","author":"NM Neary","year":"2004","unstructured":"Neary, N. M. et al. Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89, 2832\u20132836. https:\/\/doi.org\/10.1210\/jc.2003-031768 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"42446_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2217\/fon.14.14","volume":"10","author":"DC Currow","year":"2014","unstructured":"Currow, D. C. & Abernethy, A. P. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol. 10, 789\u2013802. https:\/\/doi.org\/10.2217\/fon.14.14 (2014).","journal-title":"Future Oncol."},{"key":"42446_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","volume":"21","author":"JM Garcia","year":"2013","unstructured":"Garcia, J. M., Friend, J. & Allen, S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: A multicenter, randomized, double-blind, crossover, pilot study. Support. Care Cancer 21, 129\u2013137. https:\/\/doi.org\/10.1007\/s00520-012-1500-1 (2013).","journal-title":"Support. Care Cancer"},{"key":"42446_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1470-2045(14)71154-4","volume":"16","author":"JM Garcia","year":"2015","unstructured":"Garcia, J. M. et al. Anamorelin for patients with cancer cachexia: An integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 16, 108\u2013116. https:\/\/doi.org\/10.1016\/S1470-2045(14)71154-4 (2015).","journal-title":"Lancet Oncol."},{"key":"42446_CR13","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1007\/s00520-016-3144-z","volume":"24","author":"K Takayama","year":"2016","unstructured":"Takayama, K. et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: Results of a randomized phase 2 trial. Support. Care Cancer 24, 3495\u20133505. https:\/\/doi.org\/10.1007\/s00520-016-3144-z (2016).","journal-title":"Support. Care Cancer"},{"key":"42446_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel, J. S. et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17, 519\u2013531. https:\/\/doi.org\/10.1016\/s1470-2045(15)00558-6 (2016).","journal-title":"Lancet Oncol."},{"key":"42446_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jcsm.12675","volume":"12","author":"H Wakabayashi","year":"2021","unstructured":"Wakabayashi, H., Arai, H. & Inui, A. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: Facts and numbers. J. Cachexia Sarcopenia Muscle 12, 14\u201316. https:\/\/doi.org\/10.1002\/jcsm.12675 (2021).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"42446_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2017.07.023","volume":"112","author":"K Nishie","year":"2017","unstructured":"Nishie, K., Yamamoto, S., Nagata, C., Koizumi, T. & Hanaoka, M. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis. Lung Cancer 112, 25\u201334. https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.023 (2017).","journal-title":"Lung Cancer"},{"key":"42446_CR17","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00520-016-3560-0","volume":"25","author":"Y Bai","year":"2017","unstructured":"Bai, Y. et al. Anamorelin for cancer anorexia-cachexia syndrome: A systematic review and meta-analysis. Support. Care Cancer 25, 1651\u20131659. https:\/\/doi.org\/10.1007\/s00520-016-3560-0 (2017).","journal-title":"Support. Care Cancer"},{"key":"42446_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ https:\/\/doi.org\/10.1136\/bmj.n71 (2021).","journal-title":"BMJ"},{"key":"42446_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ https:\/\/doi.org\/10.1136\/bmj.l4898 (2019).","journal-title":"BMJ"},{"key":"42446_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.zefq.2009.05.023","volume":"103","author":"HJ Sch\u00fcnemann","year":"2009","unstructured":"Sch\u00fcnemann, H. J. GRADE: From grading the evidence to developing recommendations. A description of the system and a proposal regarding the transferability of the results of clinical research to clinical practice. Z Evidenz Fortbild. Qual. Gesundh. 103, 391\u2013400. https:\/\/doi.org\/10.1016\/j.zefq.2009.05.023 (2009).","journal-title":"Z Evidenz Fortbild. Qual. Gesundh."},{"key":"42446_CR21","unstructured":"[Software]., G. G. G. G. D. T. GRADEpro GDT. Version accessed 1 April 2023. McMaster University and Evidence Prime (2022)."},{"key":"42446_CR22","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4. . The Cochrane Collaboration, 2020 (2020)."},{"key":"42446_CR23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"Katakami, N. et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124, 606\u2013616. https:\/\/doi.org\/10.1002\/cncr.31128 (2018).","journal-title":"Cancer"},{"key":"42446_CR24","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","volume":"28","author":"D Currow","year":"2017","unstructured":"Currow, D. et al. ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann. Oncol. 28, 1949\u20131956. https:\/\/doi.org\/10.1093\/annonc\/mdx192 (2017).","journal-title":"Ann. Oncol."},{"key":"42446_CR25","doi-asserted-by":"publisher","first-page":"8500","DOI":"10.1200\/jco.2005.01.8010","volume":"23","author":"T Yavuzsen","year":"2005","unstructured":"Yavuzsen, T., Davis, M. P., Walsh, D., LeGrand, S. & Lagman, R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J. Clin. Oncol. 23, 8500\u20138511. https:\/\/doi.org\/10.1200\/jco.2005.01.8010 (2005).","journal-title":"J. Clin. Oncol."},{"key":"42446_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1200\/jco.1993.11.1.152","volume":"11","author":"CL Loprinzi","year":"1993","unstructured":"Loprinzi, C. L., Schaid, D. J., Dose, A. M., Burnham, N. L. & Jensen, M. D. Body-composition changes in patients who gain weight while receiving megestrol acetate. J. Clin. Oncol. 11, 152\u2013154. https:\/\/doi.org\/10.1200\/jco.1993.11.1.152 (1993).","journal-title":"J. Clin. Oncol."},{"key":"42446_CR27","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1517\/14656560902960162","volume":"10","author":"C Madeddu","year":"2009","unstructured":"Madeddu, C., Macci\u00f2, A., Panzone, F., Tanca, F. M. & Mantovani, G. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin. Pharmacother. 10, 1359\u20131366. https:\/\/doi.org\/10.1517\/14656560902960162 (2009).","journal-title":"Expert Opin. Pharmacother."},{"key":"42446_CR28","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/1097-0142(197406)33","volume":"33","author":"CG Moertel","year":"1974","unstructured":"Moertel, C. G., Schutt, A. J., Reitemeier, R. J. & Hahn, R. G. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33, 1607\u20131609. https:\/\/doi.org\/10.1002\/1097-0142(197406)33 (1974).","journal-title":"Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42446-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T18:23:46Z","timestamp":1700331826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42446-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42446"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-42446-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2838619\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15257"}}